Medpace (NASDAQ:MEDP) Reaches New 12-Month High - Should You Buy?

Key Points

• Medpace Holdings, Inc. achieved a new 52-week high stock price of $506.55, currently trading at $498.22 with a market capitalization of $13.98 billion.
• Equities analysts have mixed opinions, with a consensus "Reduce" rating and a price target of $422.27, while recent upgrades and downgrades reflect diverse perspectives on the company's stock.
• Insider sales have been notable, with VP Susan Burwig and CEO August J. Troendle selling significant amounts of stock, reflecting a decrease in their holdings.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $506.55 and last traded at $498.22, with a volume of 122746 shares traded. The stock had previously closed at $490.77.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MEDP shares. Cowen lowered Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Jefferies Financial Group boosted their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a research note on Tuesday, September 9th. Barclays boosted their price objective on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Robert W. Baird boosted their price objective on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Rothschild & Co Redburn lowered Medpace from a "buy" rating to a "neutral" rating and increased their price objective for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Reduce" and an average target price of $422.27.

Medpace Stock Down 0.7%

The company has a fifty day moving average price of $446.89 and a two-hundred day moving average price of $355.45. The firm has a market capitalization of $14.01 billion, a price-to-earnings ratio of 37.07, a P/E/G ratio of 3.14 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, VP Susan E. Burwig sold 10,000 shares of the firm's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the transaction, the vice president directly owned 57,500 shares in the company, valued at approximately $27,600,000. This trade represents a 14.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the company's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the transaction, the director owned 10,197 shares in the company, valued at approximately $4,742,012.88. This trade represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 in the last 90 days. Insiders own 20.30% of the company's stock.

Institutional Investors Weigh In On Medpace

Hedge funds have recently modified their holdings of the stock. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group boosted its stake in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after acquiring an additional 71 shares during the period. Whittier Trust Co. lifted its position in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares during the last quarter. Employees Retirement System of Texas acquired a new position in shares of Medpace during the second quarter valued at $36,000. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Medpace in the 1st quarter worth $60,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.